Inflammatory Bowel Disease Drugs Market By Type (Ulcerative Colitis, Crohns Disease), By Drug Class (TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global inflammatory bowel disease drugs market was valued at $20,988 million in 2021 and is projected to reach $34.513.56 million by 2031 registering a CAGR of 5.1% from 2022 to 2031.
Inflammatory bowel disease is a group of disorders that causes chronic inflammation in the intestine and it is a type of gastrointestinal disease. It includes ulcerative colitis and Crohn’s disease, and both these types of diseases effect on digestive system. The prolonged inflammation of these diseases leads to damage of the gastrointestinal tract. The ulcerative colitis causes inflammation to the large intestine in the digestive tract and causes other non-digestive problems. Whereas, Crohn’s disease causes inflammation in any part of the digestive tract and it mainly affects the end part of the small intestine.
The main factors that foster the growth of the inflammatory bowel disease drugs market are alarming increase in number of chronic inflammatory bowel diseases, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for ulcerative colitis drugs. In addition, according to the survey conducted by Marc D Basson on Ulcerative Colitis, in 2019, about one million people were affected with UC. Moreover, as per Crohn’s and Colitis Foundation (CCFA), in 2020, around 70,000 cases of inflammatory bowel disease were diagnosed in the U.S. Thus, rise in number of cases of ulcerative colitis disease drives the growth of the market. Furthermore, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 10 million people suffering from inflammatory bowel disease in 2020 across the world and about 3.4 million in Europe. Furthermore, ECCFA has collaborated with Medscape to conduct training session on biosimilars for the treatment of inflammatory bowel disease. Thus, factors such as rise in prevalence of inflammatory bowel disease and collaboration among private institutions to develop new solutions for the treatment of the diseases propels the growth of the market.
In addition, increase in approval of biosimilars such as Inflectra, Imraldi, and Hyrimoz is expected to rise the adoption of effective treatment. In addition, the presence of other drugs such as IXFI which is launch by Pfizer Inc. and Cyltezo by Boehringer Ingelheim is expected to fuel the growth of the market. For instance, in September 2019, Janssen Biotech Inc. has received an FDA approval for its STELARA (ustekinumab) drug for the treatment of ulcerative colitis. STELARA is the first approved drug for ulcerative colitis which targets interleukin-12 and interleukin-23 cytokines. The interleukin-12 and interleukin-23 cytokines plays an important role in inflammatory and immune disease responses. It provides improvement of the intestinal tract as assessed by a novel histologic endoscopic mucosal improvement endpoint. In addition, in February 2022, Johnson & Johnson has introduced the safety and efficacy of Tremfya drug which is currently approved for the treatment of psoriasis but now it pushes to use for the treatment of Crohn’s and ulcerative colitis. Thus, increase in approval of biologics and biosimilars for the treatment of Crohn’s disease and ulcerative colitis by key players contribute towards the growth of the market.
In Western World, it was reported that there were increase in incidences of inflammatory bowel disease by about 0.6% out of the overall population in Canada. The prevalence of inflammatory bowel disease is increasing rapidly in developed countries. Moreover, in recent years the metagenomics research, bio-information analysis technology has begun to emerge in medical research field which contribute to inflammatory bowel disease treatment research greatly. Thus, rise in new trends in the treatment of inflammatory bowel disease drives the growth of the market. According to the Indian Journal of Medical Research, in 2021, the prevalence of inflammatory bowel disease has increasing due to lack of hygiene. The study shows that around 200 Crohn’s disease patients from Vellore, India. Thus, rise in issues regarding to personal hygiene drives the growth of the market. Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the inflammatory bowel disease drugs market. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase the demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Smoking is a factor that is consistently associated with inflammatory bowel disease. For instance, according to Indian Journal of Medical Research in 2021, there were 65% prevalence of smoking in Asians. Thus, increase in frequency of smoking increases the risk of ulcerative colitis, which is expected to contribute toward the growth of the inflammatory bowel disease drugs market. However, patent expiry and availability of alternative surgery option for inflammatory bowel disease treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs and Crohn’s disease drugs .This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The inflammatory bowel disease drugs market is studied across type, drug class, and distribution channel. On the basis of type, the market is segmented into ulcerative colitis, and Crohn’s disease. By drug class, the market is fragmented into TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players mentioned in the report are AbbVie Inc., Bristol Myers Squibb, Celltrion Healthcare, Eli-Lilly, Johnson & Johnson Services Inc., Merck & Co, Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., and UCB S.A
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inflammatory bowel disease drugs market analysis from 2021 to 2031 to identify the prevailing inflammatory bowel disease drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the inflammatory bowel disease drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global inflammatory bowel disease drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Ulcerative Colitis
Crohns Disease
By Drug Class
TNF inhibitors
Corticosteroids
Aminosalicylates
JAK inhibitors
Anti-integrin
IL inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Pfizer Inc.
UCB S.A.
Johnson & Johnson Services, Inc.
Novartis AG
Bristol Myers Squibb
ELI-LILLY
Merck & Co. Inc.
Celltrion Healthcare Co.,Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Ulcerative Colitis
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Crohns Disease
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 TNF inhibitors
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Corticosteroids
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Aminosalicylates
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 JAK inhibitors
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Anti-integrin
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 IL inhibitors
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- 5.8 Others
- 5.8.1 Key market trends, growth factors and opportunities
- 5.8.2 Market size and forecast, by region
- 5.8.3 Market analysis by country
- CHAPTER 6: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Drug Store and Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Drug Class
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Drug Class
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Drug Class
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Drug Class
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Drug Class
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Drug Class
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Drug Class
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Drug Class
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Drug Class
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Drug Class
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Drug Class
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Drug Class
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Drug Class
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Drug Class
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Drug Class
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Drug Class
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Drug Class
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Drug Class
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Drug Class
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Drug Class
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Drug Class
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Drug Class
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Takeda Pharmaceutical Company Limited
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 AbbVie Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Pfizer Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 UCB S.A.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Johnson & Johnson Services, Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Novartis AG
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Bristol Myers Squibb
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 ELI-LILLY
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Merck & Co. Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Celltrion Healthcare Co.,Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 2. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR ULCERATIVE COLITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR ULCERATIVE COLITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR CROHNS DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR CROHNS DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 7. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR TNF INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR TNF INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 9. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR AMINOSALICYLATES, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR AMINOSALICYLATES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR JAK INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR JAK INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR ANTI-INTEGRIN, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR ANTI-INTEGRIN, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR IL INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR IL INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 22. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. INFLAMMATORY BOWEL DISEASE DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 33. U.S. INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 34. U.S. INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 35. U.S. INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 36. CANADA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 37. CANADA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 38. CANADA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 39. MEXICO INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 40. MEXICO INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 41. MEXICO INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 42. EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 43. EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 44. EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 45. EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 46. GERMANY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 47. GERMANY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 48. GERMANY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 49. FRANCE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 50. FRANCE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 51. FRANCE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 52. UK INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 53. UK INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 54. UK INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 55. ITALY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 56. ITALY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 57. ITALY INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 58. SPAIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 59. SPAIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 60. SPAIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 68. JAPAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 69. JAPAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 70. JAPAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 71. CHINA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 72. CHINA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 73. CHINA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 74. AUSTRALIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 75. AUSTRALIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 77. INDIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 78. INDIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 79. INDIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 80. SOUTH KOREA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 83. REST OF ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 86. LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 87. LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 88. LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 89. LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 90. BRAZIL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 91. BRAZIL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 93. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 94. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 96. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 97. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 99. REST OF LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 100. REST OF LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 102.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
- TABLE 103.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
- TABLE 104.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
- TABLE 105.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
- TABLE 106.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
- TABLE 107.ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 108.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 109.ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 110.ABBVIE INC.: NET SALES,
- TABLE 111.ABBVIE INC.: KEY STRATERGIES
- TABLE 112.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 113.PFIZER INC.: OPERATING SEGMENTS
- TABLE 114.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 115.PFIZER INC.: NET SALES,
- TABLE 116.PFIZER INC.: KEY STRATERGIES
- TABLE 117.UCB S.A.: COMPANY SNAPSHOT
- TABLE 118.UCB S.A.: OPERATING SEGMENTS
- TABLE 119.UCB S.A.: PRODUCT PORTFOLIO
- TABLE 120.UCB S.A.: NET SALES,
- TABLE 121.UCB S.A.: KEY STRATERGIES
- TABLE 122.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
- TABLE 123.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
- TABLE 124.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
- TABLE 125.JOHNSON & JOHNSON SERVICES, INC.: NET SALES,
- TABLE 126.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES
- TABLE 127.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 128.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 129.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 130.NOVARTIS AG: NET SALES,
- TABLE 131.NOVARTIS AG: KEY STRATERGIES
- TABLE 132.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 133.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 134.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 135.BRISTOL MYERS SQUIBB: NET SALES,
- TABLE 136.BRISTOL MYERS SQUIBB: KEY STRATERGIES
- TABLE 137.ELI-LILLY: COMPANY SNAPSHOT
- TABLE 138.ELI-LILLY: OPERATING SEGMENTS
- TABLE 139.ELI-LILLY: PRODUCT PORTFOLIO
- TABLE 140.ELI-LILLY: NET SALES,
- TABLE 141.ELI-LILLY: KEY STRATERGIES
- TABLE 142.MERCK & CO. INC.: COMPANY SNAPSHOT
- TABLE 143.MERCK & CO. INC.: OPERATING SEGMENTS
- TABLE 144.MERCK & CO. INC.: PRODUCT PORTFOLIO
- TABLE 145.MERCK & CO. INC.: NET SALES,
- TABLE 146.MERCK & CO. INC.: KEY STRATERGIES
- TABLE 147.CELLTRION HEALTHCARE CO.,LTD. : COMPANY SNAPSHOT
- TABLE 148.CELLTRION HEALTHCARE CO.,LTD. : OPERATING SEGMENTS
- TABLE 149.CELLTRION HEALTHCARE CO.,LTD. : PRODUCT PORTFOLIO
- TABLE 150.CELLTRION HEALTHCARE CO.,LTD. : NET SALES,
- TABLE 151.CELLTRION HEALTHCARE CO.,LTD. : KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.INFLAMMATORY BOWEL DISEASE DRUGS MARKET SEGMENTATION
- FIGURE 2.INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031
- FIGURE 3.INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.INFLAMMATORY BOWEL DISEASE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.INFLAMMATORY BOWEL DISEASE DRUGS MARKET,BY TYPE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ULCERATIVE COLITIS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CROHNS DISEASE INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 15.INFLAMMATORY BOWEL DISEASE DRUGS MARKET,BY DRUG CLASS,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF TNF INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AMINOSALICYLATES INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF JAK INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ANTI-INTEGRIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF IL INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 23.INFLAMMATORY BOWEL DISEASE DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACY INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 27.INFLAMMATORY BOWEL DISEASE DRUGS MARKET BY REGION,2021
- FIGURE 28.U.S. INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 29.CANADA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 30.MEXICO INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 31.GERMANY INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 32.FRANCE INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 33.UK INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 34.ITALY INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 35.SPAIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 36.REST OF EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 37.JAPAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 38.CHINA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 39.AUSTRALIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 40.INDIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 41.SOUTH KOREA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 42.REST OF ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 43.BRAZIL INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 44.SAUDI ARABIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 45.SOUTH AFRICA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 46.REST OF LAMEA INFLAMMATORY BOWEL DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 50.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 51.COMPETITIVE DASHBOARD
- FIGURE 52.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 53.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
- FIGURE 54.ABBVIE INC..: NET SALES ,($MILLION)
- FIGURE 55.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 56.UCB S.A..: NET SALES ,($MILLION)
- FIGURE 57.JOHNSON & JOHNSON SERVICES, INC..: NET SALES ,($MILLION)
- FIGURE 58.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 59.BRISTOL MYERS SQUIBB.: NET SALES ,($MILLION)
- FIGURE 60.ELI-LILLY.: NET SALES ,($MILLION)
- FIGURE 61.MERCK & CO. INC..: NET SALES ,($MILLION)
- FIGURE 62.CELLTRION HEALTHCARE CO.,LTD. .: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook